<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366166">
  <stage>Registered</stage>
  <submitdate>5/05/2014</submitdate>
  <approvaldate>20/05/2014</approvaldate>
  <actrnumber>ACTRN12614000529640</actrnumber>
  <trial_identification>
    <studytitle>Effects of vitamin D on insulin resistance and endothelial dysfunction in diabetic patients with ischemic heart disease</studytitle>
    <scientifictitle>Effects of vitamin D administration vs. placebo on insulin resistance, endothelial dysfunction and inflammatory markers in diabetic patients with ischemic heart disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes </healthcondition>
    <healthcondition>ischemic heart disease</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Adminstration of a single dose parenteral vitamin D 300000 IU or placebo to diabetic patients with ischemic heart disease</interventions>
    <comparator>Placebo contains all of the excipient in oil execpt the active substance vitamin D</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Lowering Inflammatory marker, hs-CRP, based on measuring serum level</outcome>
      <timepoint>2 month</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Improving insulin resistance based on HOMA-IR model</outcome>
      <timepoint>2 month</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Alleviation of endothelial function based on ICAM-1 and VCAM-1 measured level</outcome>
      <timepoint>2 month</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with diagnosis of type 2 Diabetes mellitus on the basis of ADA criteria and ischemic heart disease based on angiography results</inclusivecriteria>
    <inclusiveminage>25</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>62</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. History of hypersensivity to Vitamin D
2. Renal failure
3.Hypercalcemia
4. Pregnant women
5. Lactating women
6.Hepatic failure (Child-Pugh B and C)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>20/04/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state>Tehran</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Shahid Beheshti University of medical Sciences</primarysponsorname>
    <primarysponsoraddress>Velenjak, near Talighani hospital, 3rd street, tehran, Tehran, Iran PO box: 14397-65461</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Shahid Beheshti University of medical Sciences</fundingname>
      <fundingaddress>Velenjak, near Talighani hospital, 3rd street, tehran, Tehran, Iran PO box: 14397-65461</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Hypovitaminosis D is a common problem and has negative effects on cardiovascular and metabolic disease like diabetes. So we want to try the effects of Vitamin D vs. placebo on inflammatory and cardiovascular markers and insulin resistance.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics committee, Shahid Beheshti University of Medical Sciences</ethicname>
      <ethicaddress>Velenjak, near Talighani hospital, 3rd street, Tehran, Tehran, Iran PO box: 14397-65462</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Mohammad abbasinazari</name>
      <address>Velenjak, near Talighani hospital, 3rd street, Tehran, Tehran, Iran,Shahid Beheshti University of medical sciences  PO box: 14397-65461</address>
      <phone>+98 2188873704</phone>
      <fax />
      <email>Farshadpharm@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Elnaz Shaseb</name>
      <address>Velenjak, near Talighani hospital, 3rd street, Tehran, Tehran, Iran,Shahid Beheshti University of medical sciences  PO box: 14397-65461</address>
      <phone>+98 2188873704</phone>
      <fax />
      <email>Elnaz_shaseb_64@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Elnaz Shaseb</name>
      <address>Velenjak, near Talighani hospital, 3rd street, Tehran, Tehran, Iran,Shahid Beheshti University of medical sciences  PO box: 14397-65461</address>
      <phone>+98 2188873704</phone>
      <fax />
      <email>Elnaz_shaseb_64@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Elnaz Shaseb</name>
      <address>Velenjak, near Talighani hospital, 3rd street, Tehran, Tehran, Iran,Shahid Beheshti University of medical sciences  PO box: 14397-65461</address>
      <phone>+98 2188873704</phone>
      <fax />
      <email>Elnaz_shaseb_64@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>